Analysis of mRNA Therapeutics and Vaccines: Analytical approaches must keep pace to ensure the identity, safety, and efficacy of evolving mRNA candidates.

Detalles Bibliográficos
Publicado en:Pharmaceutical Technology Europe Vol. 34; no. 2; pp. 9 - 14
Autor principal: Challener, Cynthia A.
Formato: pictorial tables/charts Journal Article
Publicado: MJH Life Sciences Feb2022
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=155423685&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 155423685
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        17537967
        5NG
      jtl: Pharmaceutical Technology Europe
      issn: 17537967
      maglogo: N
    pubinfo:
      dt: Feb2022
      vid: 34
      iid: 2
      pid: 54670
      pub: MJH Life Sciences
      place: Cranbury, New Jersey
    artinfo:
      ui:
        155423685
        155423685
        155423685
        155423685
      ppf: 9
      ppct: 5
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Analysis of mRNA Therapeutics and Vaccines: Analytical approaches must keep pace to ensure the identity, safety, and efficacy of evolving mRNA candidates.
      aug:
        au: Challener, Cynthia A.
      sug:
        subj:
          RNA, Messenger
          COVID-19 Vaccines
          Safety
          Vaccine Efficacy
          Nanoparticles
          Drug Development
          Microscopy, Electron Utilization
          Polymerase Chain Reaction
          Sequence Analysis
          Technology, Medical Trends
      pubtype: Trade Publication
      doctype:
        pictorial
        tables/charts
        Journal Article
      ougenre: Article
      ab:
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N